Friday, April 22, 2016 10:04:13 AM
SIALYLATED GLYCOPROTEINS
"
[0101] In some embodiments, methods described herein are useful for controlling the sialylation of a reference polypeptide (e.g., a reference glycoprotein). In some embodiments, polypeptide (e.g., glycoprotein) preparations described herein have predetermined or target levels of glycans (e.g., branched glycans having a sialic acid on an .alpha.1,3 arm, and/or branched glycans having a sialic acid on an .alpha.1,6 arm, and/or branched glycans having a sialic acid on an .alpha.1,3 arm and on an .alpha.1,6 arm), where the predetermined levels are substantially similar to or different from (e.g., higher or lower than) levels of glycans (e.g., branched glycans having a sialic acid on an .alpha.1,3 arm, and/or branched glycans having a sialic acid on an .alpha.1,6 arm, and/or branched glycans having a sialic acid on an .alpha.1,3 arm and on an .alpha.1,6 arm) in a reference polypeptide product (e.g., glycoprotein product). Nonlimiting, exemplary reference glycoprotein products can include abatacept (Orencia.RTM., Bristol-Myers Squibb), abciximab (ReoPro.RTM., Roche), adalimumab (Humira.RTM., Bristol-Myers Squibb), aflibercept (Eylea.RTM., Regeneron Pharmaceuticals), alefacept (Amevive.RTM., Astellas Pharma), alemtuzumab (Campath.RTM., Genzyme/Bayer), basiliximab (Simulect.RTM., Novartis), belatacept (Nulojix.RTM., Bristol-Myers Squibb), belimumab (Benlysta.RTM., GlaxoSmithKline), bevacizumab (Avastin.RTM., Roche), canakinumab (Ilaris.RTM., Novartis), brentuximab vedotin (Adcetris.RTM., Seattle Genetics), certolizumab (CIMZIA.RTM., UCB, Brussels, Belgium), cetuximab (Erbitux.RTM., Merck-Serono), daclizumab (Zenapax.RTM., Hoffmann-La Roche), denileukin diftitox (Ontak.RTM., Eisai), denosumab (Prolia.RTM., Amgen; Xgeva.RTM., Amgen), eculizumab (Soliris.RTM., Alexion Pharmaceuticals), efalizumab (Raptiva.RTM., Genentech), etanercept (Enbrel.RTM., Amgen-Pfizer), gemtuzumab (Mylotarg.RTM., Pfizer), golimumab (Simponi.RTM., Janssen), ibritumomab (Zevalin.RTM., Spectrum Pharmaceuticals), infliximab (Remicade.RTM., Centocor), ipilimumab (Yervoy.TM., Bristol-Myers Squibb), muromonab (Orthoclone OKT3.RTM., Janssen-Cilag), natalizumab (Tysabri.RTM., Biogen Idea, Elan), ofatumumab (Arzerra.RTM., GlaxoSmithKline), omalizumab (Xolair.RTM., Novartis), palivizumab (Synagis.RTM., Medlmmune), panitumumab (Vectibix.RTM., Amgen), ranibizumab (Lucentis.RTM., Genentech), rilonacept (Arcalyst.RTM., Regeneron Pharmaceuticals), rituximab (MabThera.RTM., Roche), tocilizumab (Actemra.RTM., Genentech; RoActemra, Hoffman-La Roche) tositumomab (Bexxar.RTM., GlaxoSmithKline), and trastuzumab (Herceptin.RTM., Roche). “
Boing X 2
Endexx Corporation (EDXC) Leverages Global Market Trends and Legislative Reforms to Spearhead Growth in the Cannabis and Plant-Based Wellness Sectors • EDXC • Mar 27, 2024 3:01 PM
Applied UV, Inc. Announces Pricing of $2.76 Million Registered Direct and Private Placement Priced at the Market Under Nasdaq Rules • AUVI • Mar 27, 2024 2:51 PM
POET and MultiLane Collaborate to Develop High-Speed Pluggable Transceivers for AI Networks • POET • Mar 27, 2024 10:52 AM
Maybacks Global Entertainment Opens 23 More Stations in Important Major Cities • AHRO • Mar 27, 2024 9:00 AM
NxGen Brands Inc. Forecast to Deliver 140% Growth in Q1 2024 • NXGB • Mar 27, 2024 7:30 AM
Kona Gold Beverages, Inc. Strategic Advancements: Covert LLC Introduces Federally Legal D9 Gummies and Revamps Innovative eCommerce Platform, Propelling Toward $12 Million Annual Revenue Goal • KGKG • Mar 26, 2024 8:30 AM